Analytical Data
-
基因名
Lpa
- Application
-
别名
Lp(a); AK38; APOA; LP; Sinking Pre-β-Lipoprotein
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P08519
-
表达区间
Asp1719~Arg2038
-
分子量
39kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme that plays a crucial role in lipid metabolism and cardiovascular disease. It is primarily produced by macrophages and is associated with low-density lipoprotein (LDL) particles in the bloodstream. Elevated levels of Lp-PLA2 have been linked to atherosclerosis and coronary artery disease, making it a potential biomarker for cardiovascular risk assessment. The enzyme catalyzes the hydrolysis of oxidized phospholipids, leading to the release of lysophosphatidylcholine and free fatty acids, which can promote inflammatory responses and plaque instability. Consequently, Lp-PLA2 has emerged as a target for therapeutic intervention, inspiring research into the development of Lp-PLA2 inhibitors that could mitigate cardiovascular events. Recent advances in recombinant protein technology have enabled the production of Lp-PLA2 in a more standardized and effective manner, allowing researchers to better understand its biochemical properties and interactions within biological systems. By elucidating the structure-function relationship of Lp-PLA2 through recombinant protein studies, scientists are aiming to clarify its role in disease pathogenesis and to explore its potential as a drug target, thus opening new avenues for the prevention and treatment of cardiovascular diseases.
